RxDoctor Payments Data

Parker Grow, MD

Interventional Cardiology · Athens, GANPI 1346335536

Payments from drug & device makers

$5,125in general payments, 2019–2025

Across 175 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$286
  • Novartis$274
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$222
  • Amgen$155
  • Shockwave Medical, Inc$140
  • plus $611 from 16 others

What the payments were for

  • Food & beverage$5,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,125 in reported general payments places this provider in the 30th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$189,198
Medicare patients
2,722
Services billed
8,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$253,880
EntrestoSacubitril/Valsartan59$69,200
XareltoRivaroxaban64$56,596
Repatha SureclickEvolocumab69$48,222
JardianceEmpagliflozin33$41,491
MultaqDronedarone Hcl19$23,455
FarxigaDapagliflozin Propanediol18$18,668
BrilintaTicagrelor37$15,953
Praluent PenAlirocumab15$11,288
Atorvastatin Calcium450$4,043
Metoprolol Succinate312$3,286
Potassium Chloride115$2,566
Ranolazine ErRanolazine16$1,999
Prasugrel Hcl35$1,934
Rosuvastatin Calcium160$1,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$253,880255 claims
NovartisEntresto$274$69,20059 claims
Johnson & JohnsonXarelto$63$56,59664 claims
Boehringer IngelheimJardiance$16$41,49133 claims
AstraZenecaFarxiga, Brilinta$62$34,62155 claims
Sanofi-aventis U.S. LLCMultaq$29$23,45519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →